BMO Capital Starts Ambit Biosciences (AMBI) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/3/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Jersey Mike's Subs files for IPO on NYSE under ticker JMKE
- AXT-Tongmei signs 3-year wafer supply deal with Coherent
Leerink Swann Starts Ambit Biosciences (AMBI) at Outperform
June 10, 2013 7:51 AM EDTLeerink Swann initiated coverage on Ambit Biosciences (NASDAQ: AMBI) with an Outperform rating and a price target of $14.00.
Analyst Howard Liang said, "In an area where chemotherapy remains as the standard of care with limited breakthrough, we see AMBI's quizartinib as the best-in-class FLT3... More
Citi Starts Ambit Biosciences (AMBI) at Buy
June 10, 2013 7:08 AM EDTCiti initiates coverage on Ambit Biosciences (NASDAQ: AMBI) with a Buy. PT $13.00.
For an analyst ratings summary and ratings history on Ambit Biosciences click here. For more ratings news on Ambit Biosciences click here.
Shares of Ambit Biosciences closed at $7.79 yesterday, with a 52 week range of $6.22-$8.24.... More
